Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparisons of adalimumab with etanercept, infliximab, and ustekinumab

P203

  • Signorovitch, James
  • Mulani, Parvez
  • Gupta, Shiraz
  • Bao, Yanjun

  • 1Analysis Group, Boston, MA, United States

    2Abbott Laboratories, Abbott Park, IL, United States

    3Abbott Laboratories, Abbott Park, IL, United States

    4Abbott Laboratories, Abbott Park, IL, United States

Commercial support: This study is sponsored by Abbott Laboratories

Journal of the American Academy of Dermatology 62(3):p AB3, March 2010.
Copyright © 2010 by Mosby, Inc.